Pharmacokinetic variability in the adolescent: Implications of body size and organ function for dosage regimen design
- 1 December 1994
- journal article
- research article
- Published by Elsevier in Journal of Adolescent Health
- Vol. 15 (8) , 654-662
- https://doi.org/10.1016/s1054-139x(94)90633-5
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liverPharmacogenetics, 1994
- Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for TherapyScience, 1993
- Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related ComplexThe Journal of Clinical Pharmacology, 1992
- Concept of maximum tolerated systemic exposure and its application to phase I‐II studies of anticancer drugsMedical and Pediatric Oncology, 1991
- Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects modelsJournal of Pharmacokinetics and Biopharmaceutics, 1989
- The population pharmacokinetics of theophylline in neonates and young infantsJournal of Pharmacokinetics and Biopharmaceutics, 1989
- Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV InfectionNew England Journal of Medicine, 1988
- The use of therapeutics in adolescenceJournal of Adolescent Health Care, 1987
- Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanolJournal of Pharmaceutical Sciences, 1979
- Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adultsThe Journal of Pediatrics, 1978